NovoCure (NVCR) has attracted investor attention after recent share price moves, with the stock closing at $17.53 on 15 August 2026. The company’s returns over the past month and past 3 months frame the current discussion.

NovoCure’s recent 1 month share price return of 10.11% and year to date share price return of 33.61% contrast with a 5 year total shareholder return that declined 87.03%, suggesting short term momentum against a weaker long term record.

If NovoCure’s recent move has you thinking about other potential opportunities in healthcare technology, it could be a good moment to scan 40 healthcare AI stocks.

After a sharp move in NovoCure’s share price, the real tension now is simple. Do you commit at today’s level, or hold back and hope the valuation offers a clearer entry later on?

Most Popular NovoCure Narrative: 32.8% Undervalued

On the most followed narrative, NovoCure’s fair value of $26.07 sits well above the recent $17.53 close. This puts the current share price in the spotlight.

Validation of TTFields therapy in multiple new indications, such as pancreatic cancer (PANOVA-3) and brain metastases from non-small cell lung cancer (METIS), positions NovoCure for potential regulatory approvals and large market expansion beginning in 2026, likely driving topline revenue growth as global cancer incidence rises in the aging population.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that valuation gap for NovoCure? The narrative leans on rising device adoption, higher margins and a future earnings profile that targets a premium multiple.

Result: Fair Value of $26.07 (UNDERVALUED)

However, the NovoCure narrative also hinges on risks such as slower TTFields adoption and ongoing reimbursement uncertainty, which could quickly challenge today’s undervaluation argument.

Next Steps

With mixed signals around NovoCure, it helps to move quickly and test the story against the data yourself. To weigh both concerns and potential upside in one place, review the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond NovoCure?

If NovoCure has sharpened your focus, do not stop here. Use this momentum to review a wider set of stocks that could better match your goals.

• Target stability first by checking companies screened for resilient balance sheets and consistent fundamentals through the solid balance sheet and fundamentals stocks screener (50 results).
• Spot potential value gaps by reviewing companies that score well on quality and pricing in the 53 high quality undervalued stocks.
• Hunt for underfollowed opportunities that many investors may overlook using the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.